CRIS Current Research Information System

LOLLINI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.811
EU - Europa 7.002
AS - Asia 3.126
AF - Africa 401
SA - Sud America 107
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 7
Totale 19.465
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.734
IT - Italia 2.114
GB - Regno Unito 1.646
CN - Cina 1.257
DE - Germania 828
VN - Vietnam 730
SG - Singapore 663
SE - Svezia 603
UA - Ucraina 379
IN - India 302
CH - Svizzera 291
FR - Francia 257
IE - Irlanda 244
RU - Federazione Russa 221
ZA - Sudafrica 130
EE - Estonia 121
CI - Costa d'Avorio 113
TG - Togo 93
BG - Bulgaria 65
CA - Canada 60
BE - Belgio 48
CO - Colombia 43
ID - Indonesia 38
JO - Giordania 37
BR - Brasile 36
NL - Olanda 34
SC - Seychelles 29
FI - Finlandia 28
RO - Romania 28
JP - Giappone 26
NG - Nigeria 26
GR - Grecia 25
CL - Cile 15
IR - Iran 13
TR - Turchia 12
AT - Austria 11
ES - Italia 11
MX - Messico 11
PL - Polonia 11
AU - Australia 10
HK - Hong Kong 10
HR - Croazia 10
EG - Egitto 8
KR - Corea 8
PK - Pakistan 8
PE - Perù 6
AL - Albania 5
AR - Argentina 5
CR - Costa Rica 5
DK - Danimarca 5
EU - Europa 4
LB - Libano 4
BD - Bangladesh 3
LU - Lussemburgo 3
MD - Moldavia 3
RS - Serbia 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
PT - Portogallo 2
TH - Thailandia 2
TW - Taiwan 2
A1 - Anonimo 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IQ - Iraq 1
KE - Kenya 1
LT - Lituania 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
UZ - Uzbekistan 1
Totale 19.465
Salva come PNG Salva come JPEG
Città #
Southend 1.447
Fairfield 1.209
Chandler 880
Ashburn 668
Singapore 576
Houston 573
Woodbridge 561
Wilmington 544
Seattle 491
Ann Arbor 451
Cambridge 387
Dong Ket 365
Bologna 361
Princeton 359
Jacksonville 256
Bern 253
Dublin 241
Boardman 226
Shanghai 186
Nanjing 147
Westminster 147
Padova 139
Abidjan 113
Santa Clara 109
Berlin 107
Milan 106
Lomé 93
Jinan 80
Beijing 79
Bremen 76
Shenyang 74
Saint Petersburg 73
Frankfurt am Main 72
Turin 72
San Diego 70
Rome 67
Sofia 64
Nanchang 55
Mülheim 54
Guangzhou 52
Redwood City 52
Changsha 51
Hebei 47
Brussels 46
Jiaxing 40
Redmond 40
Tianjin 39
Jakarta 38
Medford 38
Amman 37
Falls Church 36
Los Angeles 35
Des Moines 33
Casalecchio di Reno 30
Mahé 29
Zhengzhou 28
New York 27
Haikou 26
Verona 26
Florence 24
Ottawa 24
Abeokuta 23
Dearborn 23
London 23
Naples 23
Parma 22
Amsterdam 21
Tokyo 21
Catanzaro 20
Fuzhou 20
Taiyuan 20
Taizhou 19
Hangzhou 18
Ningbo 18
Paris 18
Helsinki 17
Norwalk 17
Toronto 17
Bulle 15
Bühl 13
Catania 13
Kuban 13
Phoenix 13
Ferrara 12
Menlo Park 12
Olalla 12
Bogotá 11
Crocetta 11
Shijiazhuang 11
Wuhan 11
Crotone 10
Lanzhou 10
Lappeenranta 10
Leawood 10
San Venanzo 10
Vienna 10
Brescia 9
Napoli 9
Trieste 9
Buffalo 8
Totale 13.211
Salva come PNG Salva come JPEG
Nome #
Vaccini antitumorali 808
IFN-γ and CD38 in Hyperprogressive Cancer Development 308
Terapia genica 294
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 246
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 223
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 207
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 202
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 194
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 177
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 175
Development of a K-edge micro CT for the study of tumor angiogenesis in small animals 171
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 168
Rethinking herpes simplex virus: the way to oncolytic agents. 161
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 160
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 159
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 158
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 157
CD99 Acts as an Oncosuppressor in Osteosarcoma. 155
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 154
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 154
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 151
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 148
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 147
Virus-like particle display of HER2 induces potent anti-cancer responses 147
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 147
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 145
null 145
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 145
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 144
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 142
Cancer immunoprevention: from mice to early clinical trials 142
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 142
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 141
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 141
Oncolytic herpes virus retargeted to HER-2. 135
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 135
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY 133
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 133
Antimetastatic activity of a preventive cancer vaccine. 133
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 133
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 132
Immunoprevention and immunotherapy of mammary carcinoma 130
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 129
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 129
Immunological prevention of a multigene cancer syndrome 129
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 129
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 129
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 128
Herpesviruses as oncolytic agents 127
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 127
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 127
Modeling the competition between lung metastases and the immune system using agents. 126
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 126
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 125
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 125
Vaccines for tumour prevention 124
Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression 124
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 124
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 124
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 123
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 122
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 121
null 121
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 121
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. 120
Genetic algorithm against cancer. 120
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 120
In silico modeling and in vivo efficacy of cancer preventive vaccinations 120
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 120
CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin 119
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 119
2011: the immune hallmarks of cancer 117
45th annual meeting of the Italian Cancer Society. Bergamo, 9-12 November 2003 117
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 116
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 116
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 116
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 115
A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice. 114
Cancer immunoprevention: What can we learn from in silico models? 113
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 112
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 112
Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma 112
Preclinical HER-2 Vaccines: From Rodent to Human HER-2 111
New target antigens for cancer immunoprevention 110
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. 110
Towards a personalized schedule with triplex vaccine. 109
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 109
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 109
Immune-infiltrate characterization in localized osteosarcoma patients treated within protocol ISG-OS1. 109
Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing’s sarcoma. 109
The Promise of Preventive Cancer Vaccines 108
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 108
The molecular basis of herpesviruses as oncolytic agents. 108
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 107
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells 107
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 106
Molecular and cellular biology of rhabdomyosarcoma 105
Computational models as novel tools for cancer vaccines. 105
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 105
Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12 engineered allogeneic cell vaccine 104
Totale 14.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.798
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.798
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.646 0 0 0 0 472 462 598 641 634 328 240 271
2020/20213.019 489 171 78 146 100 155 111 264 322 188 165 830
2021/20223.446 357 118 249 170 301 209 94 247 179 224 719 579
2022/20233.856 439 451 204 502 262 268 123 202 529 152 347 377
2023/20241.494 71 166 98 152 132 181 85 271 50 98 82 108
2024/20251.824 292 542 330 277 383 0 0 0 0 0 0 0
Totale 20.046